Polypid Ltd (PYPD) Stock Price, Quote & News

Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 7 4719 5700

Website: www.polypid.com

Address:

18 Hasivim Street, Petah Tikva, Israel

TheSuper Feb. 6 at 4:03 PM

$CING Even at $7.50 this is a steal -> Patent news catalyst -> PUFDA catalyst -> 6 months out sales -> triple digits easy. Top plays: $SLS $CING $PYPD $OCGN Lotto pick: $GOSS May 15th $3 calls.

1 · Reply

TheSuper Feb. 5 at 3:58 PM

$CING She is just looking at me as we ride off into the sunset. $80 by June. Top Picks: $CING $SLS $PYPD / Lotto play $GOSS

1 · Reply

PaulWalter Feb. 4 at 1:58 PM

$PYPD I fear these guys aren't closers. They could well waste this great opportunity.

1 · Reply

NVDAMillionaire Feb. 4 at 12:44 PM

$PYPD Outstanding article that hits the mark on PYPD's current state. So if you want to refresh your PYPD insights or learn about PYPD from scratch, this is a must read. https://everyticker.com/quote/PYPD/analysis/polypid-s-d-plex100-a-breakthrough-in-surgical-infection-prevention-poised-for-market-entry-pypd

1 · Reply

TheSuper Feb. 3 at 11:38 PM

$PYPD Starter position tomorrow.

0 · Reply

NowWeKnow Feb. 3 at 8:52 PM

$PYPD OK 👌🏿 the IV on this thing says there is something coming...who ever knows spill the beans or I'll make you listen to RFK sing a Celine Dion song

1 · Reply

Finnish_boy Feb. 3 at 11:21 AM

$PYPD Nice summary in the new magazine (nothing new). Earnings next week. Interesting to hear about rolling NDA process. Also the commentary around timeline of US partnership news and NDA submission. Both will happen in late March imo. So very big news in MARCH. Now buy all you can under $5-6 levels. Stock going to $10-12 in H1. !!

1 · Reply

huskyd97 Feb. 3 at 1:06 AM

$PYPD wow, over $5. if she can homd. I think its a major level. To allow institution buys..

0 · Reply

DASmyth Feb. 2 at 11:11 PM

$PYPD Someone knows something.

0 · Reply

PaulWalter Feb. 2 at 10:10 PM

$PYPD

0 · Reply

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

Dec 16, 2025, 8:30 AM EST - 7 weeks ago

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Dec 10, 2025, 4:42 PM EST - 2 months ago

PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript

Dec 3, 2025, 8:30 AM EST - 2 months ago

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

Nov 25, 2025, 8:30 AM EST - 2 months ago

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

Nov 12, 2025, 12:51 PM EST - 3 months ago

PolyPid Ltd. (PYPD) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:30 AM EST - 3 months ago

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 8:30 AM EST - 3 months ago

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

Oct 29, 2025, 8:30 AM EDT - 3 months ago

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Sep 30, 2025, 8:45 AM EDT - 4 months ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Sep 17, 2025, 8:44 AM EDT - 5 months ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

Sep 16, 2025, 8:30 AM EDT - 5 months ago

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Sep 3, 2025, 8:30 AM EDT - 5 months ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 2, 2025, 8:30 AM EDT - 5 months ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Aug 13, 2025, 4:52 PM EDT - 6 months ago

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:30 AM EDT - 6 months ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 8:00 AM EDT - 6 months ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Jul 30, 2025, 8:00 AM EDT - 6 months ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

Jul 15, 2025, 8:00 AM EDT - 7 months ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

Jun 16, 2025, 7:20 PM EDT - 8 months ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 11, 2025, 9:42 AM EDT - 8 months ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 8 months ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 9, 2025, 8:54 AM EDT - 8 months ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 7:30 AM EDT - 8 months ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 6, 2025, 4:05 PM EDT - 8 months ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

May 30, 2025, 10:12 AM EDT - 9 months ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 20, 2025, 7:00 AM EDT - 9 months ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 14, 2025, 1:24 PM EDT - 9 months ago

PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:00 AM EDT - 9 months ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:00 AM EDT - 10 months ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 22, 2025, 7:00 AM EDT - 10 months ago

PolyPid to Participate in The Citizens Life Sciences Conference

Mar 11, 2025, 7:00 AM EDT - 11 months ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 3, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the 37th Annual ROTH Conference

Feb 12, 2025, 10:44 AM EST - 1 year ago

PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Jan 30, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 29, 2025, 7:00 AM EST - 1 year ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Dec 26, 2024, 10:31 AM EST - 1 year ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA AVXL

Dec 23, 2024, 7:22 PM EST - 1 year ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 11, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Nov 29, 2024, 1:05 PM EST - 1 year ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 13, 2024, 2:06 PM EST - 1 year ago

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Oct 30, 2024, 8:00 AM EDT - 1 year ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 21, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Sep 3, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

Aug 14, 2024, 1:25 PM EDT - 1 year ago

PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 8:31 PM EDT - 1 year ago

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

Jul 31, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

TheSuper Feb. 6 at 4:03 PM

$CING Even at $7.50 this is a steal -> Patent news catalyst -> PUFDA catalyst -> 6 months out sales -> triple digits easy. Top plays: $SLS $CING $PYPD $OCGN Lotto pick: $GOSS May 15th $3 calls.

1 · Reply

TheSuper Feb. 5 at 3:58 PM

$CING She is just looking at me as we ride off into the sunset. $80 by June. Top Picks: $CING $SLS $PYPD / Lotto play $GOSS

1 · Reply

PaulWalter Feb. 4 at 1:58 PM

$PYPD I fear these guys aren't closers. They could well waste this great opportunity.

1 · Reply

NVDAMillionaire Feb. 4 at 12:44 PM

1 · Reply

TheSuper Feb. 3 at 11:38 PM

$PYPD Starter position tomorrow.

0 · Reply

NowWeKnow Feb. 3 at 8:52 PM

$PYPD OK 👌🏿 the IV on this thing says there is something coming...who ever knows spill the beans or I'll make you listen to RFK sing a Celine Dion song

1 · Reply

Finnish_boy Feb. 3 at 11:21 AM

1 · Reply

huskyd97 Feb. 3 at 1:06 AM

$PYPD wow, over $5. if she can homd. I think its a major level. To allow institution buys..

0 · Reply

DASmyth Feb. 2 at 11:11 PM

$PYPD Someone knows something.

0 · Reply

PaulWalter Feb. 2 at 10:10 PM

$PYPD

0 · Reply

pandodark Feb. 2 at 6:23 PM

$PYPD Some news would be nice…

1 · Reply

Botmax Jan. 28 at 11:54 PM

$PYPD Very good DD carte. Bought in finally today. Helping to reduce the need for antibiotics is a massive opportunity.

0 · Reply

aak12345 Jan. 28 at 1:11 PM

$PYPD currently very limited visibility but once NDA is submitted and gets a PDUFA date it should start showing up in many scanners.

1 · Reply

Finnish_boy Jan. 27 at 10:37 AM

$PYPD 100% gains around the corner!

0 · Reply

Finnish_boy Jan. 27 at 9:56 AM

$PYPD US partnership news (Medtronic, J&J or BD) and NDA submission about in 2 months🤯 waiting game now.

0 · Reply

Finnish_boy Jan. 26 at 9:37 PM

$PYPD I am buying every potential dip near to $4.0 My position is already too big but i am super confident this baby skyrockets to $10 by March/April. NFA.

1 · Reply

m1rr0rm3 Jan. 26 at 4:46 AM

$MYSE, $PYPD, $O i'm buying these three stocks as a long term hold

0 · Reply

CARTE_BLANCHE_DEVEREAUX Jan. 25 at 4:10 AM

$PYPD My DD on POLYPID. Intentionally left out the GLP-1 angle... As I think pre-clinical efforts muddy the waters when discussing the NDA and partnership on Plex Bullish https://www.reddit.com/r/TheBlancheRanch/s/Q4JNtLV1fc

2 · Reply

PaulWalter Jan. 23 at 7:28 PM

$PYPD Its a waiting game. Absolutely crucial product for hosptals. Wait and see.

0 · Reply

robbied61 Jan. 23 at 6:10 PM

$PYPD amazing entry level wuth little risk

0 · Reply

robbied61 Jan. 21 at 5:15 PM

$PYPD ur biggest hurdle is f d a ans we cleared that bar already

0 · Reply

robbied61 Jan. 21 at 5:14 PM

$PYPD this stock is a no brainer to double digits only requires a little more time valve if you are long

0 · Reply

Market Cap	70.11M
Revenue (ttm)	0.00
Net Income (ttm)	-29.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.16

Volume	67,200
Avg Vol	83,820
Day's Range	N/A - N/A
Shares Out	15.90M
Stochastic %K	5%
Beta	1.52
Analysts	Strong Sell
Price Target	$12.25